HomeNewsIndiaAny new booster dose should work against current, future Covid strains: Randeep Guleria

Any new booster dose should work against current, future Covid strains: Randeep Guleria

"Currently the vaccines that we have in India are covering for what was originally the Wuhan strain. After that we had so many variants. And therefore if we have to have a new vaccine, it should provide cover for the circulating strains like we do for influenza," he said.

March 23, 2023 / 23:42 IST
Story continues below Advertisement
Former AIIMS Director Dr Randeep Guleria (Image Source: ANI)
Former AIIMS Director Dr Randeep Guleria (Image Source: ANI)

The Covid vaccines in use in India are providing cover for the original Wuhan strain but if the need for another booster dose is felt as new variants emerge, it should be able to provide protection against all circulating as well as future strains, according to former AIIMS director Randeep Guleria.

During an interview to PTI, he stressed on the need for two data sets - first to ascertain whether the degree of immunity is waning and secondly if the vaccines need to be tweaked when asked if it is time for another precaution dose almost a year after the first one amid the recent uptick in Covid cases.

Story continues below Advertisement

"Currently the vaccines that we have in India are covering for what was originally the Wuhan strain. After that we had so many variants. And therefore if we have to have a new vaccine, it should provide cover for the circulating strains like we do for influenza," he said.

The renowned pulmonologist, who was part of the national Covid task force, highlighted the need for research on developing vaccines which will cover not only the current circulating strains but also from the emerging variants.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show